Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition).
Vol 22, No 14S (July 15 Supplement), 2004: 3571
© 2004 American Society of Clinical Oncology

This Article Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Figer, A. Articles by De Gramont, A. Search for Related Content PubMed Articles by Figer, A. Articles by De Gramont, A.

Abstract

5-fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Hôpital Saint Antoine, Paris, France; CH de Senlis, Senlis, France; Hopital Tenon, Paris, France; Hospital Clinico de Valencia, Valencia, Spain; Clinique Saint Jean, Lyon, France; Hopital Drevon, Dijon, France; Hospital de Valdecilla, Santander, Spain; Clinique Courlancy, Reims, France

3571

Background: Pts with age over 75 years are usually excluded from randomised studies. OPTIMOX trial consisted in a phase III study for pts with conventional inclusion criteria (526 pts), comparing FOLFOX4 to FOLFOX7 x 6 cycles, followed simplified LV5FU2 x 12 cycles and FOLFOX7 reintroduction; and two exploratory studies in pts > 75 yrs (37 pts) and in pts with Alk Ph level > 3-time the UNV (63 pts), treated according to the same regimens. Methods: This report concerns the tolerance and the efficacy observed for the 37 pts aged 75 years or older. 20 pts were treated with FOLFOX4 (arm A), and 17 with FOLFOX7 - sLV5FU2 - FOLFOX7 (arm B). Characteristics of these pts were : PS 0/1–2=49/51%, LDH (normal / > normal / unknown) 51%/27%/22%, metastatic site (1/ > 1) 73/27%, alk phosp (nl/elevated/unknown) 59%/35%/6%. Results: 37 pts are evaluable for safety and 35 pts for response. Grade 3–4 toxicities (% of pts, arm A / arm B) were: neutrophils 55/24, platelets 5/0, hemoglobin 5/0, nausea-vomiting 0/12, diarrhea 5/6, neurotoxicity 20/24. Maximal toxicity per patient was grade 3–4 in 80% of arm A pts, and 59% of arm B pts. Response rate (intent-to-treat) was 59.4 % (arm A 65%; arm B 53%). Median PFS was 37 weeks (arm A 33 w; arm B 41 w) and median OS was 79 weeks (arm A 65w and arm B 90w). Moreover, in OPTIMOX study, age does not appear as a prognosis factor in a multivariate analysis. Conclusion: These results indicate that efficacy is maintained with Folfox regimens in patients >75years.

Author Disclosure

Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sanofi

Abstract presentation from the 2004 ASCO Annual Meeting